Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s
Video

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Launching: Thursday 24th April 2025
 
ADVANCED SEARCH
Log in
Top
Current Cardiology Reports
Published in:

Open Access 26-07-2023 | Cardio-Oncology (LA Baldassarre, Section Editor)

Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism

Authors: Yiqi Zhao, Hao Jia, Xiumeng Hua, Tao An, Jiangping Song

Published in: Current Cardiology Reports | Issue 8/2023

Login to get access

Abstract

Purpose of Review

The article aims to investigate the complex relationship between cancer and cardiovascular disease (CVD), with a focus on the effects of cancer treatment on cardiac health.

Recent Findings

Advances in cancer treatment have improved long-term survival rates, but CVD has emerged as a leading cause of morbidity and mortality in cancer patients. The interplay between cancer itself, treatment methods, homeostatic changes, and lifestyle modifications contributes to this comorbidity. Recent research in the field of cardio-oncology has revealed common genetic mutations, risk factors, and metabolic features associated with the co-occurrence of cancer and CVD.

Summary

This article provides a comprehensive review of the latest research in cardio-oncology, including common genetic mutations, risk factors, and metabolic features, and explores the interactions between cancer treatment and CVD drugs, proposing novel approaches for the management of cancer and CVD.
Literature
1.
Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–88.
2.
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69:363–85.PubMedCrossRef
3.
Curigliano G, Cardinale D, Dent S, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25.PubMedCrossRef
4.
Tufano A, Coppola A, Galderisi M. The growing impact of cardiovascular oncology: epidemiology and pathophysiology. Semin Thromb Hemost. 2021;47:899–906.PubMedCrossRef
5.
Abdel-Qadir H, Austin PC, Lee DS, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol. 2017;2:88–93.PubMedCrossRef
6.
Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014;32:1218–27.PubMedPubMedCentralCrossRef
7.
••Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229–361. The 2022 ESC Guidelines on cardio-oncology are an essential reference for a comprehensive review on cardio-oncology, providing up-to-date, authoritative, and multidisciplinary insights that can help shape the discussion on the management of cancer and CVD.PubMedCrossRef
8.
Guha A, Armanious M, Fradley MG. Update on cardio-oncology: novel cancer therapeutics and associated cardiotoxicities. Trends Cardiovasc Med. 2019;29:29–39.PubMedCrossRef
9.
Lenihan DJ, Fradley MG, Dent S, et al. Proceedings From the Global Cardio-Oncology Summit: The Top 10 Priorities to Actualize for CardioOncology. JACC CardioOncol. 2019;1:256–72.PubMedPubMedCentralCrossRef
10.
11.
12.
Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation, aging, and cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol. 2022;79:837–47.PubMedPubMedCentralCrossRef
13.
Masoudkabir F, Sarrafzadegan N, Gotay C, et al. Cardiovascular disease and cancer: evidence for shared disease pathways and pharmacologic prevention. Atherosclerosis. 2017;263:343–51.PubMedPubMedCentralCrossRef
14.
Lüscher TF. Cardio-oncology: low-grade inflammation as a common pathway of cancer and cardiovascular disease. Eur Heart J. 2019;40:3871–4.PubMedCrossRef
15.
Abplanalp WT, Mas-Peiro S, Cremer S, John D, Dimmeler S, Zeiher AM. Association of clonal hematopoiesis of indeterminate potential with inflammatory gene expression in patients with severe degenerative aortic valve stenosis or chronic postischemic heart failure. JAMA Cardiol. 2020;5:1170–5.PubMedCrossRef
16.
Calvillo-Argüelles O, Jaiswal S, Shlush LI, et al. Connections between clonal hematopoiesis, cardiovascular disease, and cancer: a review. JAMA Cardiol. 2019;4:380–7.PubMedCrossRef
17.
Natarajan P, Jaiswal S, Kathiresan S. Clonal hematopoiesis: somatic mutations in blood cells and atherosclerosis. Circ Genom Precis Med. 2018;11: e001926.PubMedPubMedCentralCrossRef
18.
Böhme M, Desch S, Rosolowski M, et al. Impact of clonal hematopoiesis in patients with cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol. 2022;80:1545–56.PubMedCrossRef
19.
Pascual-Figal DA, Bayes-Genis A, Díez-Díez M, et al. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. J Am Coll Cardiol. 2021;77:1747–59.PubMedCrossRef
20.
Aavik E, Babu M, Ylä-Herttuala S. DNA methylation processes in atheosclerotic plaque. Atherosclerosis. 2019;281:168–79.PubMedCrossRef
21.
Fuster JJ, MacLauchlan S, Zuriaga MA, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842–7.PubMedPubMedCentralCrossRef
22.
Senguttuvan NB, Subramanian V, Venkatesan V, Muralidharan TR, Sankaranarayanan K. Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular diseases-an updated systematic review. J Genet Eng Biotechnol. 2021;19:105.PubMedPubMedCentralCrossRef
23.
Uddin MDM, Nguyen NQH, Yu B, et al. Clonal hematopoiesis of indeterminate potential, DNA methylation, and risk for coronary artery disease. Nat Commun. 2022;13:5350.PubMedPubMedCentralCrossRef
24.
Sano S, Oshima K, Wang Y, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J Am Coll Cardiol. 2018;71:875–86.PubMedPubMedCentralCrossRef
25.
Cobo I, Tanaka TN, Chandra Mangalhara K, et al. DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages. Immunity. 2022;55.
26.
Heyde A, Rohde D, McAlpine CS, et al. Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell. 2021;184.
27.
28.
Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Ann Oncol. 2017;28:1776–87.PubMedCrossRef
29.
Drumond-Bock AL, Bieniasz M. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis. Mol Cancer. 2021;20:145.PubMedPubMedCentralCrossRef
30.
Szczepanski AP, Zhao Z, Sosnowski T, Goo YA, Bartom ET, Wang L. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer. Genome Med. 2020;12:63.PubMedPubMedCentralCrossRef
31.
Mu J, Zhang D, Tian Y, Xie Z, Zou M-H. BRD4 inhibition by JQ1 prevents high-fat diet-induced diabetic cardiomyopathy by activating PINK1/Parkin-mediated mitophagy in vivo. J Mol Cell Cardiol. 2020;149.
32.
Ray KK, Nicholls SJ, Buhr KA, et al. Effect of apabetalone added to standard therapy on major adverse cardiovascular events in patients with recent acute coronary syndrome and type 2 diabetes: a randomized clinical trial. JAMA. 2020;323:1565–73.PubMedPubMedCentralCrossRef
33.
Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A. Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology Primer. JACC CardioOncol. 2022;4:616–23.PubMedPubMedCentralCrossRef
34.
Tulotta C, Lefley DV, Moore CK, et al. IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. NPJ Breast Cancer. 2021;7:95.PubMedPubMedCentralCrossRef
35.
Finke D, Heckmann MB, Frey N, Lehmann LH. Cancer-a major cardiac comorbidity with implications on cardiovascular metabolism. Front Physiol. 2021;12:729713.PubMedPubMedCentralCrossRef
36.
Karlstaedt A, Zhang X, Vitrac H, et al. Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc Natl Acad Sci U S A. 2016;113:10436–41.PubMedPubMedCentralCrossRef
37.
Martin SG, Berthelot-Grosjean M. Polar gradients of the DYRK-family kinase Pom1 couple cell length with the cell cycle. Nature. 2009;459:852–6.PubMedCrossRef
38.
Becker W. A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy. FEBS J. 2018;285:1203–11.PubMedCrossRef
39.
Zhuang L, Jia K, Chen C, et al. DYRK1B-STAT3 drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics. Circulation. 2022;145:829–46.PubMedCrossRef
40.
Li Y, Xie X, Jie Z, et al. DYRK1a mediates BAFF-induced noncanonical NF-κB activation to promote autoimmunity and B-cell leukemogenesis. Blood. 2021;138:2360–71.PubMedPubMedCentralCrossRef
41.
Lan C, Chen C, Qu S, et al. Inhibition of DYRK1A, via histone modification, promotes cardiomyocyte cell cycle activation and cardiac repair after myocardial infarction. EBioMedicine. 2022;82: 104139.PubMedPubMedCentralCrossRef
42.
Zhu X, Song G, Zhang S, et al. Asialoglycoprotein receptor 1 functions as a tumor suppressor in liver cancer via inhibition of STAT3. Cancer Res. 2022;82:3987–4000.PubMedCrossRef
43.
Wang J-Q, Li L-L, Hu A, et al. Inhibition of ASGR1 decreases lipid levels by promoting cholesterol excretion. Nature. 2022;608:413–20.PubMedCrossRef
44.
Huynh K. Genetics: Variants in ASGR1 linked to reduced CAD risk. Nat Rev Cardiol. 2016;13:442.PubMed
45.
Karlstaedt A, Taegtmeyer H. Cardio-onco-metabolism - metabolic vulnerabilities in cancer and the heart. J Mol Cell Cardiol. 2022;171:71–80.PubMedCrossRef
46.
•Uryga A, Gray K, Bennett M. DNA damage and repair in vascular disease. Annu Rev Physiol. 2016;78:45–66. This article reviews the relationship between cardiovascular diseases and cancers from the perspective of metabolic disorders and reprogramming, providing a reference for the prevention, diagnosis and treatment strategies of cancer-related cardiovascular diseases.PubMedCrossRef
47.
Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16.
48.
Mukherjee S, Luedeke DM, McCoy L, Iwafuchi M, Zorn AM. SOX transcription factors direct TCF-independent WNT/β-catenin responsive transcription to govern cell fate in human pluripotent stem cells. Cell Rep. 2022;40: 111247.PubMedPubMedCentralCrossRef
49.
Li L, Yang W-T, Zheng P-S, Liu X-F. SOX17 restrains proliferation and tumor formation by down-regulating activity of the Wnt/β-catenin signaling pathway via trans-suppressing β-catenin in cervical cancer. Cell Death Dis. 2018;9:741.PubMedPubMedCentralCrossRef
50.
Hsieh C-H, Kuan W-H, Chang W-L, et al. Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma. J Biomed Sci. 2022;29:90.PubMedPubMedCentralCrossRef
51.
Zhu N, Welch CL, Wang J, et al. Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Med. 2018;10:56.PubMedPubMedCentralCrossRef
52.
53.
do Valle HA, Kaur P, Kwon JS, Cheifetz R, Dawson L, Hanley GE. Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: a population-based study. Gynecol Oncol. 2021;162:707–714.
54.
Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23:78–94.PubMedCrossRef
55.
Yang J, Hall JE, Jose PA, Chen K, Zeng C. Comprehensive insights in GRK4 and hypertension: from mechanisms to potential therapeutics. Pharmacol Ther. 2022;239:108194.PubMedPubMedCentralCrossRef
56.
Matsubayashi J, Takanashi M, Oikawa K, et al. Expression of G protein-coupled receptor kinase 4 is associated with breast cancer tumourigenesis. J Pathol. 2008;216:317–27.PubMedCrossRef
57.
Luo Y, Wang Z, Xiao S, Li R, Jiang X. G protein-coupled receptor kinase 4 is a novel prognostic factor in hepatocellular carcinoma. Dis Markers. 2022;2022:2628879.PubMedPubMedCentralCrossRef
58.
Karlstaedt A, Barrett M, Hu R, Gammons ST, Ky B. Cardio-oncology: understanding the intersections between cardiac metabolism and cancer biology. JACC Basic Transl Sci. 2021;6:705–18.PubMedPubMedCentralCrossRef
59.
Mili N, Paschou SA, Goulis DG, Dimopoulos M-A, Lambrinoudaki I, Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74:478–97.PubMedCrossRef
60.
Katta N, Loethen T, Lavie CJ, Alpert MA. Obesity and coronary heart disease: epidemiology, pathology, and coronary artery imaging. Curr Probl Cardiol. 2021;46:100655.PubMedCrossRef
61.
Singh A, Mayengbam SS, Yaduvanshi H, Wani MR, Bhat MK. Macrophage functionality in obesity favors cancer progression. Cancer Res. 2022.
62.
Renfro LA, Loupakis F, Adams RA, et al. Body mass index is prognostic in metastatic colorectal cancer: pooled analysis of patients from first-line clinical trials in the ARCAD database. J Clin Oncol. 2016;34:144–50.PubMedCrossRef
63.
Kasi PM, Zafar SY, Grothey A. Is obesity an advantage in patients with colorectal cancer? Expert Rev Gastroenterol Hepatol. 2015;9:1339–42.PubMedCrossRef
64.
Lavie CJ, Ventura HO. The obesity paradox in heart failure: is it all about fitness, fat, or sex? JACC Heart Fail. 2015;3:927–30.PubMedCrossRef
65.
Yun J-S, Ko S-H. Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism. 2021;123:154838.PubMedCrossRef
66.
Newman JD, Schwartzbard AZ, Weintraub HS, Goldberg IJ, Berger JS. Primary prevention of cardiovascular disease in diabetes mellitus. J Am Coll Cardiol. 2017;70:883–93.PubMedPubMedCentralCrossRef
67.
Pektas MB, Turan O, Ozturk Bingol G, Sumlu E, Sadi G, Akar F. High glucose causes vascular dysfunction through Akt/eNOS pathway: reciprocal modulation by juglone and resveratrol. Can J Physiol Pharmacol. 2018;96:757–64.PubMedCrossRef
68.
Irace C, Carallo C, Scavelli F, De Franceschi MS, Esposito T, Gnasso A. Blood viscosity in subjects with normoglycemia and prediabetes. Diabetes Care. 2014;37:488–92.PubMedCrossRef
69.
Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010;60:207–21.PubMedCrossRef
70.
Satija A, Spiegelman D, Giovannucci E, Hu FB. Type 2 diabetes and risk of cancer. BMJ. 2015;350:g7707.PubMedCrossRef
71.
Icard P, Shulman S, Farhat D, Steyaert J-M, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38.
72.
Selvaraj S, Kelly DP, Margulies KB. Implications of altered ketone metabolism and therapeutic ketosis in heart failure. Circulation. 2020;141:1800–12.PubMedPubMedCentralCrossRef
73.
Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Ketone body utilization drives tumor growth and metastasis. Cell Cycle. 2012;11:3964–71.PubMedPubMedCentralCrossRef
74.
Bellahcène A, Nokin M-J, Castronovo V, Schalkwijk C. Methylglyoxal-derived stress: an emerging biological factor involved in the onset and progression of cancer. Semin Cancer Biol. 2018;49:64–74.PubMedCrossRef
75.
Lee JH, Subedi L, Kim SY. Effect of cysteine on methylglyoxal-induced renal damage in mesangial cells. Cells. 2020;9.
76.
Schalkwijk CG, Stehouwer CDA. Methylglyoxal, a highly reactive dicarbonyl compound, in diabetes, its vascular complications, and other age-related diseases. Physiol Rev. 2020;100:407–61.PubMedCrossRef
77.
Šilhavý J, Malínská H, Hüttl M, et al. Downregulation of the gene is associated with reduced adiposity and ectopic fat accumulation in spontaneously hypertensive rats. Antioxidants (Basel). 2020;9.
78.
Sakellariou S, Fragkou P, Levidou G, et al. Clinical significance of AGE-RAGE axis in colorectal cancer: associations with glyoxalase-I, adiponectin receptor expression and prognosis. BMC Cancer. 2016;16:174.PubMedPubMedCentralCrossRef
79.
Jandova J, Wondrak GT. Genomic GLO1 deletion modulates TXNIP expression, glucose metabolism, and redox homeostasis while accelerating human A375 malignant melanoma tumor growth. Redox Biol. 2021;39:101838.PubMedCrossRef
80.
Jandial R, Neman J, Lim PP, et al. Inhibition of GLO1 in glioblastoma multiforme increases DNA-AGEs, stimulates RAGE expression, and inhibits brain tumor growth in orthotopic mouse models. Int J Mol Sci. 2018;19.
81.
Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism. 2013;62:1543–52.PubMedCrossRef
82.
Agarwal N, Taberner FJ, Rangel Rojas D, et al. SUMOylation of enzymes and ion channels in sensory neurons protects against metabolic dysfunction, neuropathy, and sensory loss in diabetes. Neuron. 2020;107.
83.
84.
Li N, Zhang S, Xiong F, Eizirik DL, Wang C-Y. SUMOylation, a multifaceted regulatory mechanism in the pancreatic beta cells. Semin Cell Dev Biol. 2020;103:51–8.PubMedCrossRef
85.
86.
87.
Wang T, Wu J, Dong W, et al. The MEK inhibitor U0126 ameliorates diabetic cardiomyopathy by restricting XBP1’s phosphorylation dependent SUMOylation. Int J Biol Sci. 2021;17:2984–99.PubMedPubMedCentralCrossRef
88.
Steinbichler TB, Dudás J, Riechelmann H, Skvortsova I-I. The role of exosomes in cancer metastasis. Semin Cancer Biol. 2017;44:170–81.PubMedCrossRef
89.
Chen C, Zheng H, Luo Y, et al. SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer. J Clin Invest. 2021;131.
90.
Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61:21–8.PubMedCrossRef
91.
Liu W, Chakraborty B, Safi R, Kazmin D, Chang C-Y, McDonnell DP. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. Nat Commun. 2021;12:5103.PubMedPubMedCentralCrossRef
92.
Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol. 2010;28:4649–57.PubMedCrossRef
93.
Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342:1094–8.PubMedPubMedCentralCrossRef
94.
Pereira S, Cline DL, Glavas MM, Covey SD, Kieffer TJ. Tissue-Specific effects of leptin on glucose and lipid metabolism. Endocr Rev. 2021;42.
95.
96.
Fonfara S, Kitz S, Hetzel U, Kipar A. Myocardial leptin transcription in feline hypertrophic cardiomyopathy. Res Vet Sci. 2017;112:105–8.PubMedCrossRef
97.
Khokhlova A, Myachina T, Butova X, et al. The acute effects of leptin on the contractility of isolated rat atrial and ventricular cardiomyocytes. Int J Mol Sci. 2022;23.
98.
McGaffin KR, Witham WG, Yester KA, et al. Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice. Cardiovasc Res. 2011;89:60–71.PubMedCrossRef
99.
Martin SS, Qasim A, Reilly MP. Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol. 2008;52:1201–10.PubMedPubMedCentralCrossRef
100.
101.
Gogiraju R, Hubert A, Fahrer J, et al. Endothelial leptin receptor deletion promotes cardiac autophagy and angiogenesis following pressure overload by suppressing Akt/mTOR signaling. Circ Heart Fail. 2019;12:e005622.PubMedCrossRef
102.
Tewari S, Vargas R, Reizes O. The impact of obesity and adipokines on breast and gynecologic malignancies. Ann N Y Acad Sci. 2022.
103.
104.
Zhang C, Yue C, Herrmann A, et al. STAT3 activation-induced fatty acid oxidation in CD8 T effector cells is critical for obesity-promoted breast tumor growth. Cell Metab.  2020;31.
105.
Ren G, Guo J-H, Feng C-L, et al. Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model. Mol Ther Oncolytics. 2022;26:372–86.PubMedPubMedCentralCrossRef
106.
Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43:280–99.PubMedCrossRef
107.
108.
Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104:971–7.PubMedCrossRef
109.
Galán-Arriola C, Villena-Gutiérrez R, Higuero-Verdejo MI, et al. Remote ischaemic preconditioning ameliorates anthracycline-induced cardiotoxicity and preserves mitochondrial integrity. Cardiovasc Res. 2021;117:1132–43.PubMedCrossRef
110.
Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139: 111708.PubMedCrossRef
111.
Saito T, Hamano K, Sadoshima J. Molecular mechanisms and clinical implications of multiple forms of mitophagy in the heart. Cardiovasc Res. 2021;117:2730–41.PubMedCrossRef
112.
Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res. 2002;62:4592–8.PubMed
113.
Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8.PubMedCrossRef
114.
Petrykey K, Andelfinger GU, Laverdière C, Sinnett D, Krajinovic M. Genetic factors in anthracycline-induced cardiotoxicity in patients treated for pediatric cancer. Expert Opin Drug Metab Toxicol. 2020;16:865–83.PubMedCrossRef
115.
Yang X, Li G, Yang T, et al. Possible susceptibility genes for intervention against chemotherapy-induced cardiotoxicity. Oxid Med Cell Longev. 2020;2020:4894625.PubMedPubMedCentralCrossRef
116.
117.
118.
Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. Curr Oncol Rep. 2021;23:128.PubMedPubMedCentralCrossRef
119.
Kurokawa YK, Shang MR, Yin RT, George SC. Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Toxicol Lett. 2018;285:74–80.PubMedCrossRef
120.
van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 2021;7:978–84.PubMedCrossRef
121.
122.
Kitani T, Ong S-G, Lam CK, et al. Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer. Circulation. 2019;139:2451–65.PubMedPubMedCentralCrossRef
123.
White AJ, LaGerche A, Toner GC, Whitbourn RJ. Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist. Int J Cardiol. 2009;131:e92–4.PubMedCrossRef
124.
125.
Lynce F, Barac A, Geng X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175:595–603.PubMedPubMedCentralCrossRef
126.
Leong DP, Cosman T, Alhussein MM, et al. Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial. JACC Cardio Oncol. 2019;1.
127.
Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35:870–7.PubMedCrossRef
128.
Hullin R, Métrich M, Sarre A, et al. Diverging effects of enalapril or eplerenone in primary prevention against doxorubicin-induced cardiotoxicity. Cardiovasc Res. 2018;114:272–81.PubMedCrossRef
129.
Lother A, Bergemann S, Kowalski J, et al. Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity. Cardiovasc Res. 2018;114:282–90.PubMedCrossRef
130.
Løfling LL, Støer NC, Sloan EK, et al. β-blockers and breast cancer survival by molecular subtypes: a population-based cohort study and meta-analysis. Br J Cancer. 2022;127:1086–96.PubMedPubMedCentralCrossRef
131.
Gillis RD, Botteri E, Chang A, et al. Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients. Eur J Cancer. 2021;147:106–16.PubMedCrossRef
132.
Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol. 2018;71:2281–90.PubMedCrossRef
133.
Zhang D, Ma Q-Y, Hu H-T, Zhang M. β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. Cancer Biol Ther. 2010;10:19–29.PubMedCrossRef
134.
Cleveland KH, Yeung S, Huang KM, Liang S, Andresen BT, Huang Y. Phosphoproteome profiling provides insight into the mechanism of action for carvedilol-mediated cancer prevention. Mol Carcinog. 2018;57.
135.
Gao Y-M, Feng S-T, Wen Y, Tang T-T, Wang B, Liu B-C. Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming. EBioMedicine. 2022;83:104215.PubMedPubMedCentralCrossRef
136.
CA Gongora ZD Drobni QAC Silva T, et al. Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines. JACC Heart Fail. 2022;10:559–567.
137.
Quagliariello V, De Laurentiis M, Rea D, et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol. 2021;20:150.PubMedPubMedCentralCrossRef
138.
Ren C, Sun K, Zhang Y, et al. Sodium-glucose cotransporter-2 inhibitor empagliflozin ameliorates sunitinib-induced cardiac dysfunction via regulation of AMPK-mTOR signaling pathway-mediated autophagy. Front Pharmacol. 2021;12:664181.PubMedPubMedCentralCrossRef
139.
Wright EM, Ghezzi C, Loo DDF. Novel and unexpected functions of SGLTs. Physiology (Bethesda). 2017;32:435–43.PubMed
140.
141.
Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12–21.PubMedCrossRef
142.
Karami-Tehrani F, Moeinifard M, Aghaei M, Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res. 2012;43:470–5.PubMedCrossRef
143.
144.
Das A, Durrant D, Mitchell C, et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A. 2010;107:18202–7.PubMedPubMedCentralCrossRef
145.
Hamilton TK, Hu N, Kolomitro K, et al. Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer. World J Urol. 2013;31:325–30.PubMedCrossRef
146.
Kim JH, Kim WS, Park C. Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications. Antiviral Res. 2021;189:105063.PubMedCrossRef
147.
Chelko SP, Keceli G, Carpi A, et al. Exercise triggers CAPN1-mediated AIF truncation, inducing myocyte cell death in arrhythmogenic cardiomyopathy. Sci Transl Med. 2021;13.
148.
Wang Y, Zheng D, Wei M, et al. Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin. Cardiovasc Res. 2013;98:381–90.PubMedCrossRef
149.
Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013;14:23–34.PubMedCrossRef
150.
Ramos KN, Gregornik D, Ramos KS. Pharmacogenomics insights into precision pediatric oncology. Curr Opin Pediatr. 2021;33:564–9.PubMedCrossRef
Metadata
Title
Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism
Authors
Yiqi Zhao
Hao Jia
Xiumeng Hua
Tao An
Jiangping Song
Publication date
26-07-2023
Publisher
Springer US
Published in
Current Cardiology Reports / Issue 8/2023
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01906-6

Other articles of this Issue 8/2023

Clinical Features of Takotsubo Syndrome and Its Differential Diagnostic Criteria in Clinical Nursing Practice: A Review of the Literature

  • Open Access
  • Care
  • Myocardial Disease (A Abbate and M Merlo, Section Editors)

Can dietary supplements help lipid lowering for CV health?

Correction to: Echo Doppler Parameters of Diastolic Function

  • Correction

Risk of Cardiac Implantable Electronic Device Infection in Patients with Bloodstream Infection: Microbiologic Effect in the Era of Positron Emission Tomography–Computed Tomography

Incidence and Prevalence of Atrial Fibrillation in Latinos: What’s New Since the Study in Latinos (SOL)?

The Dicrotic Notch: Mechanisms, Characteristics, and Clinical Correlations

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases
Image Credits